317 related articles for article (PubMed ID: 15718384)
1. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.
Chelikani PK; Haver AC; Reidelberger RD
Am J Physiol Regul Integr Comp Physiol; 2005 Jun; 288(6):R1695-706. PubMed ID: 15718384
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
3. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats.
Chelikani PK; Haver AC; Reidelberger RD
Diabetes; 2006 Nov; 55(11):3038-46. PubMed ID: 17065340
[TBL] [Abstract][Full Text] [Related]
4. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats.
Chelikani PK; Haver AC; Reidelberger RD
Endocrinology; 2005 Feb; 146(2):879-88. PubMed ID: 15539554
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
6. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
Long SJ; Sutton JA; Amaee WB; Giouvanoudi A; Spyrou NM; Rogers PJ; Morgan LM
Br J Nutr; 1999 Apr; 81(4):273-9. PubMed ID: 10999014
[TBL] [Abstract][Full Text] [Related]
7. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
8. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.
Wettergren A; Schjoldager B; Mortensen PE; Myhre J; Christiansen J; Holst JJ
Dig Dis Sci; 1993 Apr; 38(4):665-73. PubMed ID: 8462365
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.
Gutniak MK; Svartberg J; Hellström PM; Holst JJ; Adner N; Ahrén B
J Intern Med; 2001 Jul; 250(1):81-7. PubMed ID: 11454146
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
11. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
12. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
Delgado-Aros S; Kim DY; Burton DD; Thomforde GM; Stephens D; Brinkmann BH; Vella A; Camilleri M
Am J Physiol Gastrointest Liver Physiol; 2002 Mar; 282(3):G424-31. PubMed ID: 11841992
[TBL] [Abstract][Full Text] [Related]
13. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.
Flint A; Raben A; Ersbøll AK; Holst JJ; Astrup A
Int J Obes Relat Metab Disord; 2001 Jun; 25(6):781-92. PubMed ID: 11439290
[TBL] [Abstract][Full Text] [Related]
14. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
[TBL] [Abstract][Full Text] [Related]
15. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
[TBL] [Abstract][Full Text] [Related]
16. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.
Näslund E; Bogefors J; Skogar S; Grybäck P; Jacobsson H; Holst JJ; Hellström PM
Am J Physiol; 1999 Sep; 277(3):R910-6. PubMed ID: 10484511
[TBL] [Abstract][Full Text] [Related]
17. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
18. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men.
Steinert RE; Schirra J; Meyer-Gerspach AC; Kienle P; Fischer H; Schulte F; Goeke B; Beglinger C
Am J Clin Nutr; 2014 Aug; 100(2):514-23. PubMed ID: 24965303
[TBL] [Abstract][Full Text] [Related]
19. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.
Nagell CF; Wettergren A; Pedersen JF; Mortensen D; Holst JJ
Scand J Gastroenterol; 2004 Apr; 39(4):353-8. PubMed ID: 15125467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
